Algeria

Reimbursed Care Access

Algeria maintains a prohibitionist, tightly regulated regime for psychoactive/hallucinogenic substances: national narcotics and psychotropes law explicitly criminalises trafficking, possession and use (with narrow medical/scientific exemptions) while the health system uses certain controlled substances (notably ketamine) for approved medical/anesthetic purposes. There is no established, reimbursed clinical program for classical psychedelic therapies (psilocybin, MDMA, mescaline, DMT, 5‑MeO‑DMT, ibogaine, ayahuasca, 2C‑X) outside of specially authorised research; most of those compounds are treated as illicit psychotropic/stupefiant substances under Law No. 04‑18 and its implementing rules. [https://www.unodc.org/cld/en/legislation/dza/loi_no._04-18_relative_a_la_prevention_et_a_la_repression_de_lusage_et_du_traffic_illicites_de_stupefiants/chapitre_iii/articles_12-28/loi_04-18.html|UNODC: Loi n°04-18] [https://onlcdt.mjustice.dz/onlcdt_fr/?p=legisl_2004_chap_1|ONLCDT (Algeria) – legislation summary]